Search
Iodide I-131
go.drugbank.com/drugs/DB09293ApprovedInvestigationalAs a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see … Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy.
Products: MON.IYOT-131 0.37-7400 MBQ (10µ Cİ-200 M Cİ) ORAL KAPSÜL, 10 MCİ, MON.IYOT-131 74-18500 MBQ ORAL ÇÖZELTİ İÇEREN FLAKON, 10 MCİTerbutaline
go.drugbank.com/drugs/DB00871ApprovedInvestigational[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]
Mixtures: BRELAX 1,5 MG+66,5 MG/5 ML ŞURUP, 100 ML, BİCANA 1,5 MG/5 ML + 66,5 MG/5 ML ŞURUP, 100 MLCategories: Adrenergics for Systemic Use, Drugs for Obstructive Airway DiseasesBiperiden
go.drugbank.com/drugs/DB00810ApprovedInvestigationalWithdrawnA muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol, alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanolLiraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigationalVictoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. … [Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34.
Mixtures: XULTOPHY 100U/ML+3.6MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 10 ADET, XULTOPHY 100U/ML+3.6MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADETCategories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsNitisinone
go.drugbank.com/drugs/DB00348ApprovedNitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria.
Products: NITISINONA 10 MG, NITISOR® 10 MG CAPSULASDicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]
Categories: Drugs for Functional Gastrointestinal DisordersSynonyms: 2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate, Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl esterAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalAcemetacin is a carboxymethyl ester of indometacin. … [A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E.
Products: RANTUDIL ® LP 90 MG CAPSULAS DE LIBERACIÓN PROLONGADA, RANTUDİL 90 MG UZATILMIŞ SALIMLI KAPSÜL, 10 ADETFerric carboxymaltose
go.drugbank.com/drugs/DB08917ApprovedInvestigationalFerric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.
Categories: Compounds used in a research, industrial, or household settingProducts: Ferapplic 500 mg/10 ml Enjeksiyonluk/İnfüzyonluk Çözelti, 1 flakon, Ferinject® 50 mg iron/mL solution for injection/infusionRisperidone
go.drugbank.com/drugs/DB00734ApprovedInvestigational[L12885] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets … which may responsible for some of its undesirable effects.
Categories: Adrenergic alpha-1 Receptor Antagonists, Heterocyclic Compounds, 1-RingInternational brands: Risperidal M-TabMacitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalA combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024. … Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013.
Mixtures: OPSYNVI® (MACITENTAN/TADALAFILO) 10MG/40 MG TABLETAS RECUBIERTASCategories: Heterocyclic Compounds, 1-Ring, Endothelin A Receptor Antagonists